Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Fineline Cube Mar 31, 2026
Company Deals

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Fineline Cube Mar 31, 2026
Company Deals

Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs

Fineline Cube Mar 31, 2026
Company Deals

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

Fineline Cube Mar 31, 2026
Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Fineline Cube Mar 31, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

Abbisko Therapeutics Secures FDA Clearance for ABSK061 Pediatric Achondroplasia Trial, Advancing Oral FGFR2/3 Inhibitor

Fineline Cube Mar 31, 2026
Company Drug

ImmuneOnco Doses First Patient in Phase III Trial of World’s First CD47/CD20 Bispecific for Follicular Lymphoma

Fineline Cube Mar 31, 2026
Company Medical Device

Zylox-Tonbridge Completes Patient Enrollment for ZENFLEX Study in Germany

Fineline Cube Dec 21, 2023

Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...

Company Drug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Approvals for SLE and Lymphoma Drug Candidates

Fineline Cube Dec 21, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...

Company Drug

RemeGen’s Telitacicept Secures FDA Approval for Global Phase III Study in Primary Sjogren’s Syndrome

Fineline Cube Dec 21, 2023

RemeGen (HKG: 9995), a China-based pharmaceutical company, has received approval from the US Food and...

Company

Novo Nordisk Foundation Launches $260 Million Initiative to Develop Respiratory Disease Vaccines

Fineline Cube Dec 21, 2023

Novo Nordisk Foundation, the entity that controls Denmark-based Novo Nordisk (CPH: NOVO-B), has unveiled an...

Company Deals

LianBio Board Turns Down Concentra Biosciences Buyout Offer

Fineline Cube Dec 20, 2023

China-based LianBio (OTCMKTS: LIANY) has announced that its board of directors has unanimously decided not...

Company Deals

Gilead Acquires Pre-Clinical IL-18BP Targeting Antibody Candidate from Compugen in $848 Million Deal

Fineline Cube Dec 20, 2023

Gilead (NASDAQ: GILD) has licensed a potential first-in-class IL-18 binding protein (IL-18BP) targeting antibody candidate...

Company Deals

Jiangsu Synthgene and Starna Therapeutics Join Forces in mRNA Technology Advancement

Fineline Cube Dec 20, 2023

China’s Jiangsu Synthgene Biotechnology Co., Ltd has announced a strategic partnership with Suzhou-based Starna Therapeutics,...

Company Deals

Shanghai Escugen Partners with InxMed for Global Development Rights to EZWi-Fit Platform

Fineline Cube Dec 20, 2023

Shanghai Escugen has entered into a partnership with InxMed (Nanjing) Co., Ltd, granting the Chinese...

Company Drug

RemeGen Ltd Receives FDA Clearance for MSLN-Targeting ADC RC88 in Gynecological Tumors

Fineline Cube Dec 20, 2023

China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical clearance...

Policy / Regulatory

China Announces New Hospital Inspection Measures to Standardize Healthcare System

Fineline Cube Dec 20, 2023

The National Health Commission (NHC), in collaboration with the National Administration of Traditional Chinese Medicine...

Company Deals

MSD Partners with Owkin to Develop MSI-H Biomarker Screening for Cancers

Fineline Cube Dec 20, 2023

US pharmaceutical company Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a partnership...

Company Deals

Sanofi Expands Oncology Portfolio with NK Cell Engager In-License from Innate Pharma

Fineline Cube Dec 20, 2023

Sanofi (NASDAQ: SNY) has in-licensed a natural killer (NK) cell engager candidate for solid tumors...

Company Deals

Huadong Medicine Strikes Exclusive Promotion Deal with Impact Therapeutics for Senaparib in China

Fineline Cube Dec 20, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an exclusive market promotion service...

Company Drug

Konruns Pharmaceutical Gets NMPA Approval for KC1036 Clinical Study in Juventus sarcoma

Fineline Cube Dec 20, 2023

Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has received approval from the National Medical Products...

Company Drug

Staidson Pharmaceutical’s BDB-001 Earns Breakthrough Therapy Designation in China for AAV Treatment

Fineline Cube Dec 20, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that its...

Company Drug

3SBio Subsidiary Gets Green Light for SSGJ-608 Ankylosing Spondylitis Study

Fineline Cube Dec 20, 2023

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has received...

Company Drug

Lynk Pharmaceuticals Initiates Phase III Clinical Trial for Rheumatoid Arthritis Drug in China

Fineline Cube Dec 20, 2023

China-based Lynk Pharmaceuticals Co., Ltd has announced that the first patient has been dosed in...

Company Deals

Tower Cold Chain Expands into China with Partnership with Tower & Winner Solutions

Fineline Cube Dec 20, 2023

Tower Cold Chain, a UK-based specialist in pharmaceutical container solutions, has announced a partnership with...

Company Deals

Biocytogen Pharmaceuticals Inks Antibody Deal with Neurocrine Biosciences

Fineline Cube Dec 20, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) has announced an antibody assessment and option...

Company Deals

China Grand Pharmaceuticals Secures Distribution of Sirtex’s SIR-Spheres for Liver Cancer

Fineline Cube Dec 19, 2023

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) announced that its subsidiaries, Beijing...

Posts pagination

1 … 405 406 407 … 644

Recent updates

  • Amoy Diagnostics and HutchMed Secure World’s First NMPA Approval for MET Amplification Companion Diagnostic
  • Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care
  • Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors
  • Boston Scientific Secures FDA 510(k) Clearance for Asurys Fluid Management System in Kidney Stone Procedures
  • Kailera Therapeutics Plans IPO to Fund Obesity Pipeline After Burning Through USD 347M in Development Costs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Amoy Diagnostics and HutchMed Secure World’s First NMPA Approval for MET Amplification Companion Diagnostic

Company Deals Digital

Abbott Integrates Precision Oncology Portfolio into Flatiron’s OncoEMR Platform to Streamline Cancer Care

Company Deals

Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors

Company Medical Device

Boston Scientific Secures FDA 510(k) Clearance for Asurys Fluid Management System in Kidney Stone Procedures

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.